-
Catastrophic antiphospholipid syndrome (CAPS) : descriptive analysis of a series of 280 patients from the "CAPS Registry"Cervera, Ricard ...Objective: To describe the clinical and laboratory features, as well as the precipitating factors, treatment and outcome of patients with catastrophic antiphospholipid syndrome (APS). Methods: We ... analyzed the 280 patients included until September 2008 in the website based international registry of patients with catastrophic APS ("CAPS Registry") (http://www.med.ub.es/MIMMUN/FORUM/CAPS.HTM). Results: The entire series includes 201 (72%) female and 79 (28%) male patients with a mean age of 37 +/-14 years (range, 11-60 years). A total of 129 (46%) patients suffered from primary APS, 112 (40%) from systemic lupus erythematosus, 14 (5%) from lupus-like disease, and 25 (9%) from other autoimmune diseases. The catastrophic episode was the first manifestation of the APS in 129 (46%) patients. A precipitating factor was reported in 53% of the patients. The first clinical manifestation at the time of the catastrophic episode was a pulmonary complication in 24% of the cases, a neurologic feature in 18% and a renal feature in 18%. During the catastrophic episode, intraabdominal involvement was identified in the majority of patients, mainly consisting of renal (71%), hepatic (33%), gastrointestinal (25%), splenic (19%), adrenal (13%), and pancreatic (8%) manifestations. 123 (44%) patients died at the time of the catastrophic APS event but the higher recovery rate was achieved by the combination of anticoagulants plus corticosteroids plus plasma exchange(PE) and/or intravenous immunoglobulins (IVIG) (69% versus 54%). Conclusion: The catastrophic APS is an uncommon but potentially life-threatening condition that needs high clinical awareness. The therapeutical connotation is that this may be corrected with the combination of anticoagulation plus steroids plus attempts at achieving a prompt reductionof antiphospholipid antibody titer (i.e. PE and/or IVIG).Vir: Journal of autoimmunity. - ISSN 0896-8411 (Vol. 32, iss. 3/4, 2009, str. 240-245)Vrsta gradiva - članek, sestavni delLeto - 2009Jezik - angleškiCOBISS.SI-ID - 27142873
Avtor
Cervera, Ricard |
Bucciarelli, Silvia |
Plasín, Miguel A. |
Gomez-Puerta, José A |
Plaza, Joan |
Pons-Estel, Guillermo |
Shoenfeld, Yehuda |
Ingelmo, Miguel |
Espinosa, Gerard
Drugi avtorji
Praprotnik, Sonja |
Šipek-Dolničar, Alenka
Teme
Adult |
Antibodies, Antiphospholipid |
Blood |
Anticoagulants |
Therapeutic Use |
Antiphospholipid Syndrome |
Blood |
Drug Therapy |
Immunology |
Mortality |
Catastrophic Illness |
Child |
Immunoglobulins, Intravenous |
Therapeutic Use |
Plasma Exchange |
Registries |
Statistics & Numerical Data |
Steroids |
Therapeutic Use |
Antifosfolipidni sindrom |
Otrok |
Antikoagulansi |
Imunoglobulini intravenski |
Odrasli |
Protitelesa antifosfolipidna |
Katastrofična bolezen |
Plazemska izmenjava |
Registri |
Steroidi
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Cervera, Ricard | |
Bucciarelli, Silvia | |
Plasín, Miguel A. | |
Gomez-Puerta, José A | |
Plaza, Joan | |
Pons-Estel, Guillermo | |
Shoenfeld, Yehuda | |
Ingelmo, Miguel | |
Espinosa, Gerard | |
Praprotnik, Sonja | 13602 |
Šipek-Dolničar, Alenka | 10645 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.